Intas Pharma has completed the acquisition of UDENYCA for $558 million, the company said in a release. UDENYCA is a biosimilar to Neulasta or Pegfilgrastim. It is used to treat side effects of radiation therapy in cancer patients such as recurrent infections. Intas acquired the biosimilar drug from California-based Coherus Life Sciences in December 2024….
New Delhi: The technical committee constituted for supervising clinical trials on new chemical entities has cleared Swiss drug major Roche to import and market cancer drug Atezolizumab injection (Tecentriq) through subcutaneous (SC) route-under the skin injection for Indian patients. The decisions is expected to provide relief to patients in the contry as the new subcutaneous…
Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Rectal Cancer – Dr. Poulami Basu We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link